Want to see KR:003090 full AI Analyst Report?
Daewoong Co., Ltd. (003090) AI Stock Analysis
Daewoong Co., Ltd.
(Korea Exchange:003090)
The score is driven by very attractive valuation (low P/E) but held back by weak financial quality due to negative free cash flow and increasing leverage, alongside bearish technical momentum with the price trading below key moving averages and negative MACD.
Daewoong Co., Ltd. (003090) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 635.18B
- Dividend Yield
- 1.32%
- Average Volume (3M)
- 59.52K
- Price to Earnings (P/E)
- 3.3
- Beta (1Y)
- 0.32
- Revenue Growth
- 4.55%
- EPS Growth
- 116.82%
- Country
- KR
- Employees
- 413
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Daewoong Co., Ltd. Business Overview & Revenue Model
Company Description
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transition...
Daewoong Co., Ltd. Financial Statement Overview
Summary
Revenue growth and generally solid gross margins support the business, and profitability has recovered to ~8% net margin in 2025/TTM. However, financial strength is constrained by persistently negative free cash flow (2023–TTM) and rising leverage (debt-to-equity up to ~0.78 in TTM), which increases risk if cash generation does not improve.
Income Statement
78PositiveBalance Sheet
64PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.12T | 2.07T | 1.94T | 1.82T | 1.70T | 1.51T |
| Gross Profit | 1.11T | 1.09T | 1.05T | 931.20B | 899.65B | 763.17B |
| EBITDA | 334.23B | 323.40B | 182.13B | 270.34B | 211.57B | 233.01B |
| Net Income | 179.40B | 175.06B | 57.89B | 152.67B | 102.57B | 78.73B |
Balance Sheet | ||||||
| Total Assets | 3.48T | 3.23T | 2.72T | 2.36T | 2.16T | 1.93T |
| Cash, Cash Equivalents and Short-Term Investments | 294.78B | 285.79B | 264.14B | 267.16B | 386.74B | 387.85B |
| Total Debt | 974.45B | 878.22B | 682.65B | 448.85B | 445.13B | 445.50B |
| Total Liabilities | 1.60T | 1.46T | 1.22T | 922.48B | 879.41B | 776.67B |
| Stockholders Equity | 1.25T | 1.18T | 996.51B | 934.80B | 828.83B | 730.56B |
Cash Flow | ||||||
| Free Cash Flow | -77.88B | -37.22B | -173.92B | -23.30B | 31.46B | 17.67B |
| Operating Cash Flow | 256.80B | 257.58B | 162.38B | 205.65B | 149.08B | 133.18B |
| Investing Cash Flow | -411.27B | -367.87B | -365.55B | -204.82B | -105.49B | -219.13B |
| Financing Cash Flow | 183.54B | 175.43B | 227.82B | -28.98B | 22.57B | 11.00B |
Daewoong Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003090, the sentiment is Negative. The current price of 15110.00 is below the 20-day moving average (MA) of 15290.00, below the 50-day MA of 16098.20, and below the 200-day MA of 19816.35, indicating a bearish trend. The MACD of -346.63 indicates Negative momentum. The RSI at 44.60 is Neutral, neither overbought nor oversold. The STOCH value of 30.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003090.
Daewoong Co., Ltd. Peers Comparison
Overall Rating
KR:00106071Outperform
KR:00569070Outperform- KR:00309062Neutral
KR:28513041Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:001060 | 71Outperform | KRW 555.42B | 5.49 | ― | 2.83% | 10.50% | 96.29% |
| KR:005690 | 70Outperform | KRW 563.92B | 12.12 | ― | 0.53% | 51.28% | 124.70% |
| KR:003090 | 62Neutral | KRW 617.86B | 3.25 | ― | 1.32% | 4.55% | 116.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:285130 | 41Neutral | KRW 769.28B | 107.88 | ― | 2.76% | 26.85% | -80.66% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:003090 | Daewoong Co., Ltd. | 15110.00 | -6496.22 | -30.07% | |
| KR:001060 | JW Pharmaceutical Corporation | 23000.00 | -645.26 | -2.73% | |
| KR:005690 | Pharmicell Co., Ltd | 9400.00 | -8738.31 | -48.18% | |
| KR:041960 | Komipharm International Co., Ltd | 9070.00 | 3110.00 | 52.18% | |
| KR:086450 | DongKook Pharmaceutical Co., Ltd. | 23450.00 | 6091.61 | 35.09% | |
| KR:285130 | SK Chemicals Co., Ltd. | 41650.00 | -22340.05 | -34.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026